The Minimax Risk for Two-Stage Procedures in Clinical Trials
临床试验两阶段程序的极小极大风险AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要研究临床试验分配的决策风险,而未提出因果效应识别或估计方法。
反馈分类问题临床试验两阶段程序的极小极大风险AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
SUMMARY The risk involved in a trial to compare two medical treatments is shared by patients who receive the inferior treatment during the experimental phase and those remaining after the experiment who might all receive the inferior treatment if the results are misleading. We consider the maximum of this risk with respect to the unknown probabilities of success and seek allocation rules that minimize this quantity, for a given total of patients. It needs extensive computations to find such minimax procedures, but there are simple and almost equally effective allocation rules based on a truncated sequential probability ratio test.